X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14911) 14911
Newspaper Article (2032) 2032
Newsletter (230) 230
Magazine Article (174) 174
Book Chapter (91) 91
Web Resource (83) 83
Trade Publication Article (23) 23
Book / eBook (16) 16
Government Document (14) 14
Book Review (13) 13
Reference (8) 8
Dissertation (6) 6
Streaming Video (5) 5
Conference Proceeding (4) 4
Report (3) 3
Publication (2) 2
Transcript (2) 2
Pamphlet (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11367) 11367
fatigue (9127) 9127
female (7624) 7624
male (7189) 7189
middle aged (6052) 6052
adult (5711) 5711
aged (4136) 4136
chronic fatigue syndrome (3232) 3232
quality of life (3152) 3152
oncology (2694) 2694
cancer (2469) 2469
care and treatment (2447) 2447
treatment outcome (2436) 2436
fatigue - etiology (2381) 2381
patients (2116) 2116
quality-of-life (2030) 2030
drug therapy (2000) 2000
pain (1923) 1923
research (1902) 1902
chemotherapy (1641) 1641
fatigue - chemically induced (1632) 1632
analysis (1625) 1625
depression (1564) 1564
surveys and questionnaires (1489) 1489
clinical neurology (1482) 1482
clinical trials (1461) 1461
health aspects (1384) 1384
exercise (1372) 1372
adolescent (1278) 1278
aged, 80 and over (1275) 1275
medicine & public health (1262) 1262
fatigue - drug therapy (1241) 1241
therapy (1230) 1230
sleep (1201) 1201
studies (1183) 1183
young adult (1139) 1139
neurosciences (1132) 1132
double-blind (1116) 1116
medical research (1113) 1113
medicine, general & internal (1079) 1079
risk factors (1047) 1047
prevalence (1041) 1041
animals (1037) 1037
severity of illness index (1029) 1029
medicine (1014) 1014
double-blind method (952) 952
immune system (942) 942
multiple sclerosis (931) 931
psychiatry (925) 925
nursing (917) 917
diagnosis (902) 902
pharmacology & pharmacy (893) 893
fibromyalgia (864) 864
rheumatology (859) 859
rehabilitation (845) 845
research article (819) 819
symptoms (812) 812
disease (800) 800
breast cancer (794) 794
prospective studies (782) 782
time factors (765) 765
women (742) 742
retailing industry (738) 738
health care sciences & services (721) 721
antineoplastic agents - adverse effects (715) 715
medicine, experimental (714) 714
anxiety (701) 701
neoplasms - drug therapy (685) 685
management (672) 672
fatigue - physiopathology (642) 642
neurology (642) 642
fatigue - psychology (639) 639
dose-response relationship, drug (630) 630
cross-sectional studies (621) 621
follow-up studies (621) 621
cancer therapies (616) 616
mental depression (610) 610
drug administration schedule (605) 605
abridged index medicus (603) 603
inflammation (598) 598
fatigue - epidemiology (596) 596
antineoplastic agents - therapeutic use (593) 593
impact (583) 583
antineoplastic combined chemotherapy protocols - therapeutic use (577) 577
immunology (570) 570
usage (567) 567
fatigue - diagnosis (552) 552
complications and side effects (551) 551
cancer patients (544) 544
neoplasms - complications (544) 544
physical fitness (539) 539
fatigue - therapy (532) 532
breast neoplasms - drug therapy (531) 531
child (531) 531
antineoplastic combined chemotherapy protocols - adverse effects (525) 525
capital losses (523) 523
efficacy (520) 520
depression, mental (514) 514
stress (512) 512
anemia (511) 511
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (4) 4
Online Resources - Online (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Media Commons - Microtexts (1) 1
OISE - Stacks (1) 1
Robarts - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17061) 17061
German (220) 220
French (110) 110
Chinese (78) 78
Japanese (70) 70
Russian (60) 60
Spanish (48) 48
Portuguese (31) 31
Norwegian (23) 23
Italian (21) 21
Polish (18) 18
Swedish (16) 16
Dutch (15) 15
Korean (10) 10
Danish (8) 8
Hungarian (7) 7
Turkish (6) 6
Persian (5) 5
Romanian (5) 5
Czech (3) 3
Finnish (3) 3
Lithuanian (3) 3
Ukrainian (3) 3
Afrikaans (1) 1
Bulgarian (1) 1
Hindi (1) 1
Serbian (1) 1
Slovak (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 2010, Volume 28, Issue 19, pp. 3167 - 3175
Journal Article
Current medicinal chemistry, ISSN 0929-8673, 2010, Volume 17, Issue 19, pp. 2070 - 2095
During the last 20 years, numerous clinical trials have examined the therapeutic usefulness of melatonin in different fields of medicine. The objective of this... 
Glaucoma | In vitro fertilization | Melatonin | Hemodialysis | Gastric mucosa | Clinical trials | Fibromyalgia | Sleep disturbances | Macular degeneration | Aging | Anesthesia | Smith-magenis syndrome | Depression | Crohn's disease | Chronic fatigue syndrome | Shift work | Neurological diseases | Arterial hypertension | Jet lag | Infectious diseases | Neonatal care | Rheumatoid arthritis | Irritable bowel syndrome | Diabetes | Ulcerative colitis | Smith-Magenis syndrome | glaucoma | infectious diseases | METASTATIC COLORECTAL-CANCER | anesthesia | sleep disturbances | SOLID TUMOR PATIENTS | TYPE-2 DIABETIC-PATIENTS | fibromyalgia | SLEEP-WAKE RHYTHM | in vitro fertilization | PHARMACOLOGY & PHARMACY | ulcerative colitis | clinical trials | CHRONIC-FATIGUE-SYNDROME | IRRITABLE-BOWEL-SYNDROME | gastric mucosa | shift work | CHEMISTRY, MEDICINAL | irritable bowel syndrome | BIOCHEMISTRY & MOLECULAR BIOLOGY | jet lag | rheumatoid arthritis | INTERLEUKIN-2 PLUS MELATONIN | macular degeneration | arterial hypertension | neurological diseases | PINEAL HORMONE MELATONIN | neonatal care | PRECURSOR L-TRYPTOPHAN | chronic fatigue syndrome | hemodialysis | aging | depression | PLACEBO-CONTROLLED TRIAL | diabetes | anaesthesia | Cardiovascular Diseases - drug therapy | Humans | Nervous System Diseases - drug therapy | Fatigue Syndrome, Chronic - drug therapy | Hematologic Diseases - drug therapy | Clinical Trials as Topic | Neoplasms - drug therapy | Communicable Diseases - drug therapy | Eye Diseases - drug therapy | Gastrointestinal Diseases - drug therapy | Muscular Diseases - drug therapy | Melatonin - therapeutic use | Endocrine System Diseases - drug therapy
Journal Article
Cancer, ISSN 0008-543X, 2017, Volume 123, Issue 16, pp. 3080 - 3087
BACKGROUND Mirvetuximab soravtansine (IMGN853) is an antibody‐drug conjugate that selectively targets folate receptor α (FRα... 
clinical trial | targeted therapy | folate receptor | phase 1 | antibody‐drug conjugate | antibody-drug conjugate | THERAPEUTICS | FARLETUZUMAB | PLATINUM-RESISTANT OVARIAN | MONOCLONAL-ANTIBODY | COMBINATION | EPITHELIAL OVARIAN-CANCER | CHEMOTHERAPY | DELIVERY | THERAPY | ONCOLOGY | PROTEINS | Lung Neoplasms - drug therapy | Humans | Middle Aged | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Vision Disorders - chemically induced | Aged, 80 and over | Immunoconjugates - therapeutic use | Adult | Female | Hypophosphatemia - chemically induced | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Neoplasms, Glandular and Epithelial - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Renal Cell - pathology | Maytansine - analogs & derivatives | Keratitis - chemically induced | Maytansine - therapeutic use | Disease Progression | Neoplasms - drug therapy | Maximum Tolerated Dose | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Kidney Neoplasms - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Kidney Neoplasms - drug therapy | Neoplasms - pathology | Cancer patients | Care and treatment | Pharmacokinetics | Health aspects | Analysis | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Endocrine-related cancer, ISSN 1479-6821, 2015, Volume 22, Issue 6, pp. 877 - 887
Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies... 
Adverse events | Targeted therapy | Tyrosine kinase inhibitor | Sorafenib | Differentiated thyroid cancer | targeted therapy | sorafenib | EFFICACY | GUIDELINES | TIME | adverse events | differentiated thyroid cancer | DECREASES | TRIAL | ONCOLOGY | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | tyrosine kinase inhibitor | RENAL-CELL | EXPOSURE | Adenoma, Oxyphilic - enzymology | Dyspnea - chemically induced | Thyroid Neoplasms - enzymology | Prevalence | Adenocarcinoma, Follicular - radiotherapy | Humans | Middle Aged | Drug Resistance, Neoplasm | Hypertension - drug therapy | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Protein Kinase Inhibitors - adverse effects | Weight Loss - drug effects | Incidence | Neoplasms, Second Primary - chemically induced | Adenocarcinoma, Follicular - drug therapy | Adenoma, Oxyphilic - drug therapy | Hypocalcemia - epidemiology | Niacinamide - adverse effects | Carcinoma, Papillary - drug therapy | Niacinamide - therapeutic use | Thyroid Neoplasms - radiotherapy | Adenocarcinoma, Follicular - enzymology | Neoplasms, Second Primary - epidemiology | Niacinamide - analogs & derivatives | Diarrhea - epidemiology | Diarrhea - chemically induced | Iodine Radioisotopes - therapeutic use | Hypocalcemia - chemically induced | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Female | Carcinoma, Papillary - enzymology | Hypertension - epidemiology | Adenoma, Oxyphilic - radiotherapy | Drug Eruptions - etiology | Phenylurea Compounds - therapeutic use | Dyspnea - epidemiology | Disease-Free Survival | Carcinoma, Papillary - radiotherapy | Fatigue - epidemiology | Thyroid Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Aged | Diarrhea - drug therapy | Drug Eruptions - epidemiology | Radiopharmaceuticals - therapeutic use | Index Medicus | Research
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 68, pp. 1 - 10
.... Results Forty-one patients with advanced solid tumours refractory to standard therapies and with adequate organ function were recruited in eight cohorts up to doses of 150... 
Hematology, Oncology and Palliative Medicine | Pharmacodynamics | MEK inhibitor | Phase I | Optimal biological dose | Pharmacokinetics | BRAF-MUTATED MELANOMA | MULTICENTER | SELUMETINIB PLUS DOCETAXEL | SAFETY | TRAMETINIB | CELL LUNG-CANCER | TRIAL | DOSE-ESCALATION | ONCOLOGY | DOUBLE-BLIND | AZD6244 ARRY-142886 | Lung Neoplasms - drug therapy | Pancreatic Neoplasms - metabolism | Nausea - chemically induced | Allosteric Regulation | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Fatigue - chemically induced | Ribosomal Protein S6 Kinases, 70-kDa - drug effects | Protein Kinase Inhibitors - adverse effects | Colorectal Neoplasms - drug therapy | Chromatography, Liquid | Proto-Oncogene Proteins c-akt - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | Bile Duct Neoplasms - metabolism | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Administration, Oral | Carcinoma, Non-Small-Cell Lung - metabolism | Neoplasms - drug therapy | Maximum Tolerated Dose | Mesothelioma - metabolism | Mitogen-Activated Protein Kinase 3 - metabolism | Anorexia - chemically induced | Glycogen Synthase Kinase 3 beta - drug effects | Mitogen-Activated Protein Kinase 1 - metabolism | Neoplasms - metabolism | Phosphoproteins - drug effects | Mitogen-Activated Protein Kinase 1 - drug effects | Cholangiocarcinoma - metabolism | Chromatography, High Pressure Liquid | Diarrhea - chemically induced | Mitogen-Activated Protein Kinase 3 - drug effects | Pancreatic Neoplasms - drug therapy | Tandem Mass Spectrometry | Uterine Cervical Neoplasms - metabolism | Esophageal Neoplasms - metabolism | Adult | Female | Colorectal Neoplasms - metabolism | Bile Duct Neoplasms - drug therapy | Drug Eruptions - etiology | Abdominal Pain - chemically induced | Uterine Cervical Neoplasms - drug therapy | Glycogen Synthase Kinase 3 beta - metabolism | Mesothelioma - drug therapy | Cholangiocarcinoma - drug therapy | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Esophageal Neoplasms - drug therapy | Proto-Oncogene Proteins c-akt - drug effects | Care and treatment | Protein kinases | Mitogens | Cells | Tumors
Journal Article
British journal of cancer, ISSN 1532-1827, 2017, Volume 117, Issue 1, pp. 33 - 40
Background: Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction between programmed cell death protein 1 (PD-1) on T-cells and PD-L1 and... 
clinical trial | pembrolizumab | advanced/metastatic solid tumours | phase I | chemotherapy | immunotherapy | CRITERIA | EFFICACY | CELL LUNG-CANCER | ONCOLOGY | ADVANCED MELANOMA | COHORT | NIVOLUMAB | IPILIMUMAB | Lung Neoplasms - drug therapy | Nausea - chemically induced | Humans | Middle Aged | Male | Fatigue - chemically induced | Vinblastine - administration & dosage | Diarrhea - chemically induced | Small Cell Lung Carcinoma - drug therapy | Pancreatic Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Vinblastine - analogs & derivatives | Doxorubicin - analogs & derivatives | Adult | Camptothecin - administration & dosage | Female | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Drug Eruptions - etiology | Deoxycytidine - administration & dosage | Albumins - administration & dosage | Treatment Outcome | Sarcoma - drug therapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Polyethylene Glycols - administration & dosage | Neoplasms - drug therapy | Taxoids - administration & dosage | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Index Medicus | metastatic solid tumours | advanced | Clinical Study
Journal Article
Annals of internal medicine, ISSN 0003-4819, 07/2015, Volume 163, Issue 1, pp. 1 - 13
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 2, pp. 121 - 131
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 7, pp. 621 - 631
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 8, pp. 705 - 713
Among patients coinfected with HIV-1 and HCV genotype 1 or 4 who were receiving effective antiretroviral therapy, treatment with 12 weeks of ledipasvir and sofosbuvir was associated with a sustained... 
MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | INTERFERON | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | ALPHA-2A PLUS RIBAVIRIN | VETERANS | GENOTYPE 1 INFECTION | COHORT | LIVER-DISEASE | HIV-1 | Humans | Middle Aged | Drug Resistance, Viral | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Viral Load | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Fluorenes - pharmacokinetics | Hepacivirus - isolation & purification | Anti-Retroviral Agents - therapeutic use | Antiviral Agents - therapeutic use | Benzimidazoles - pharmacokinetics | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | HIV Infections - drug therapy | Uridine Monophosphate - pharmacokinetics | Sofosbuvir | Care and treatment | Research | Hepatitis C virus | HIV infection | Emtricitabine | Headache | Antiretroviral drugs | Inhibitor drugs | Diarrhea | Fatigue | Patients | Efavirenz | Studies | Tenofovir | Cirrhosis | Genotype & phenotype | Hepatitis | Human immunodeficiency virus--HIV | Hepatitis C | Drug therapy | Genotypes
Journal Article